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Evidence suggests that coronary heart disease (CHD) is the most common outcome of hypertension. Hypertension accelerates
the development of atherosclerosis, and sustained elevation of blood pressure (BP) can destabilize vascular lesions and precipitate
acute coronary events. Hypertension can cause myocardial ischemia in the absence of CHD. These cardiovascular risks attributed
to hypertension can be reduced by optimal BP control. Although several antihypertensive agents exist, the choice of agent and
the appropriate target BP for patients with CHD remain controversial. In this succinct paper, we examine the evidence and the
mechanisms for the linkage between hypertension and CHD and we discuss the treatment options and the goals of therapy that
are consistent with the report of the seventh Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC 7) and American Heart Association scientific statement. We anticipate changes in the recommendations
of the forthcoming JNC 8.
1. Background
Hypertension is not only a major risk factor for stroke
and heart failure (HF), but more importantly for coronary
heart disease (CHD). Based on the blood pressure (BP)
cutoﬀ of ≥140/90mmHg for hypertension, as defined by
the seventh report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC 7) [1], over 65 million adult Americans,
or approximately one fourth of the American population,
have hypertension [2]. The report of the INTERHEART
study involving 52 countries all over the world showed
that hypertension conferred a greater adjusted relative risk
of acute myocardial infarction than diabetes [3]. Among
individuals aged 40 to 90 years, each 20/10mmHg rise in
BP doubles the risk of fatal coronary events [4]. Reports of
national surveys conducted in various countries in North
America, Asia, and Africa indicate that hypertension is
highly prevalent, but poorly treated and/or controlled [5].
This observation may be one reason while CHD remains
the leading cause of death and disability in the developed
countries [6] and is projected to be the leading cause of death
in the developing world by 2020 [7–9].
Hypertension accelerates the development and progres-
sion of atherosclerosis, and sustained elevation of BP can
destabilize vascular lesions and precipitate acute coronary
events. Hypertension by itself can cause myocardial ischemia
in the absence of CHD. These CVS risks attributed to
hypertension can be greatly reduced by optimal control
of BP. Although several antihypertensive agents exist, the
optimal choice of agents and the appropriate target BP
for patients with CHD remain controversial. The goals of
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treating patients with hypertension and CHD are to lower
BP, reduce ischemia, and prevent CVS events.
In this succinct paper, we examine the epidemiological
evidence and the pathophysiological mechanisms for the
linkage between hypertension and CHD and we discuss the
treatment options and the goals of therapy that are consistent
with the recommendations of JNC 7 and American Heart
Association (AHA) scientific statement [1, 10]. As more
data from hypertension trials become available, we anticipate
changes in the recommendations of the forthcoming JNC 8.
2. Link between Hypertension and Coronary
Heart Disease
The pathophysiological link between hypertension and CHD
can be described under two major pathways as described
below and shown in Figure 1.
2.1. Atherogenesis. The physical impact of high BP can
cause endothelial injury. Injured endothelium results in
impairment in the synthesis and the release of the potent
vasodilator—nitric oxide and also promotes the accumu-
lation of reactive oxygen species and other inflammatory
factors which mediate the development of atherosclerosis,
thrombosis, and vascular occlusion. This inflammatory
process is a prominent feature in the pathogenesis of both
hypertension and atherosclerosis [11]. Some mechanisms
such as the rennin-angiotensin-aldosterone system (RAAS)
and the sympathetic nervous system that maintain hyperten-
sion are also those that promote atherosclerosis. Angiotensin
II increases BP and facilitates progression of atherosclerosis
through vasoconstrictive and vascular remodeling eﬀects.
This observation led to the idea that some antihyperten-
sive agents such as angiotensin-converting enzyme (ACE)
inhibitors may have beneficial eﬀects on atherosclerosis and
CHD in addition to their BP lowering eﬀect [12].
2.2. Increased Afterload and Left Ventricular Hypertrophy.
Hypertension by itself can cause myocardial ischemia in the
absence of CHD. Increased afterload due to hypertension
can result in significant left ventricular hypertrophy (LVH),
which may impair ventricular relaxation and compromise
coronary blood flow during diastole. Although genetic
factors have been associated with LVH, chronic uncontrolled
hypertension appears to be the major cause [13, 14].
Research has shown that LVH diminishes coronary flow
reserve [15] and independently predicts future CHD, HF,
stroke, and sudden cardiac death [16].
3. Therapy for Hypertension in CHD
Both JNC 7 and 2007 AHA guideline stressed the importance
of antihypertensive therapy in the high-risk population,
including CHD [1, 9]. In JNC 7, target BP was defined
for general population and patients with diabetes, HF, and
renal disease, but not for those with CHD. However, AHA
guideline clarified this issue and recommended the same
target BP of 130/80mmHg as for other high-risk population
with caution in lowering the DBP below 60 mmHg which



















Figure 1: Pathophysiological link between hypertension and coro-
nary heart disease.
hypertension in patients with CHD are to lower BP, reduce
ischemia, and prevent cardiovascular events and death. To
achieve these goals, both nonpharmacological interventions
and pharmacological therapy are recommended as described
below.
3.1. Nonpharmacological Interventions. Nonpharmacologi-
cal interventions should be encouraged in all individuals
with hypertension [1]. Exercise improves cardiac function,
reduces BP and cardiac afterload by a variety of mech-
anisms, including reduced arterial stiﬀness [17]. Research
has shown that physical activity predicts the likelihood
of CVS disease beyond that explained by the commonly
measured cardiometabolic risk factors [18]. Although the
mechanism is not entirely clear, evidence indicates that exer-
cise improves coronary artery flow reserves in CHD patients
[19] and pathophysiological mechanisms that are potentially
important in generating CHD have been linked to physical
activity [20]. Hence, regular exercise is recommended in all
individuals with hypertension and CHD.
Studies have also shown that various lifestyle behaviors,
including unhealthy diet, physical inactivity, and smoking,
promote the development and clinical manifestations of
CHD [21]. Therefore, lifestyle changes and adoption of
healthful behaviors are equally important in the manage-
ment of hypertension and CHD. Special attention should
be given to weight loss, diet control, salt intake, alcohol
consumption, smoking, and stress management.
3.2. Pharmacological Treatment. Pharmacological treatment
is inevitable in high-risk populations such as those with
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CHD, although lifestyle modifications alone may suﬃce
in the general population with prehypertension. The rec-
ommended target BP for individuals with CHD or CHD
equivalents: diabetes mellitus, chronic renal disease, periph-
eral arterial disease, carotid artery disease, and abdominal
aortic aneurysm is <130/80mmHg [9]. Although several
antihypertensive agents exist, it is not completely clear
whether all antihypertensive agents are equally eﬀective in
preventing or decreasing progression of CHD. Here, we
discuss each agent and provide the evidence in support of
their use.
3.3. Beta-Blockers. The treatment of hypertension in CHD
patients should begin with β-blockers as first-line therapy,
unless contraindicated [22–25]. Relative contraindications to
their use include hypotension, severe bronchospastic lung
disease, decompensated HF, sinus or atrioventricular node
dysfunction, and severe peripheral vascular disease. Also,
diabetic patients with significant history of hypoglycemic
episodes should use β-blockers with great caution because of
the risk of masking symptoms of hypoglycemia.
β-blockers are heterogenous class of agents with diﬀering
pharmacological eﬀects. The cardioselective β-blockers with-
out intrinsic sympathomimetic activity are generally pre-
ferred. These agents reduce myocardial oxygen consumption
and heart rate and enhance coronary flow by increasing
diastolic filling period. Among patients with both acute
myocardial infarction (MI) and hypertension, β-Blockers
have been shown to limit infarct size, improve survival,
and decrease the risk of recurrent MI and the incidence of
sudden cardiac death, which is secondary to fatal arrhyth-
mias [26–28]. While metoprolol, carvedilol, and bisoprolol
were shown to improve outcomes in HF patients, atenolol-
based therapy was found to be inferior to amlodipine-based
therapy in reducing CVS events in the Anglo-Scandinavian
Cardiac Outcomes Trial (ASCOT) [29]. Similarly, a substudy
of ASCOT, the Conduit Artery Function Evaluation (CAFE´),
showed that Atenolol was less eﬀective in reducing systolic BP
and cardiac afterload than amlodipine [30], which perhaps
could be explained by the observation of increased arterial
stiﬀness and aortic wave reflections in patients using beta-
blockers [31]. Hence, in the absence of MI, CHD, or HF,
the use of β-blockers as first-line therapy for hypertension
is controversial and not supported.
3.4. Calcium Channel Blockers. Long-acting dihydropyri-
dines calcium channel blockers (CCBs), amlodipine, and
nifedipine can be added to the basic regimen if BP remains
elevated or angina continues while on β-blocker therapy.
The nondihydropyridine agents, diltiazem and verapamil,
can also be substituted for β-blocker when contraindications
exist or side eﬀects develop [32]. Although nondihydropyri-
dine CCBs can be used as antianginal in combination with
a β-blocker, there is associated risk of severe bradycardia
or atrioventricular block. Therefore, if a CCB is needed in
addition to β-blocker to control angina or BP, it should be a
long-acting dihydropyridine CCB. These agents decrease BP
by causing vasodilation and decreasing peripheral resistance
and wall tension, thus reducing myocardial O2 demand.
They also increase myocardial O2 supply by dilating coronary
arteries.
Several large randomized trials have evaluated the use of
CCBs in hypertension control. The Controlled-Onset Vera-
pamil IN Cardiovascular Endpoint (CONVINCE) trial, the
NORdic DILtiazem (NORDIL) study, and the International
VErapamil SR/Trandolapril (INVEST) study showed that
outcomes with CCBs-based therapy were not diﬀerent from
those of β-blockers-based therapy [33–35]. Based on these
studies, CCBs appear to be good substitutes for β-blockers
in the treatment of angina in hypertensive patients; however,
they are not recommended for secondary prevention because
of their inability to prevent ventricular dilatation and HF
[36–40]. Hence, nondihydropyridine agents should not be
used in patients with systolic HF [41] and short-acting
dihydropyridine CCBs should be avoided in patients with
acute MI, pulmonary edema, or LV dysfunction [24, 42, 43].
The role of CCBs in the prevention of CVS events among
patients with CHD remains unclear, and several studies that
evaluated CVS outcome with the use of CCBs have yielded
mixed results [35, 37–40, 44, 45].
3.5. Nitrates. Nitrates have not been shown to be of sig-
nificant use in hypertension treatment; however, they are
indicated for acute relief of angina or treatment of chronic
angina which cannot be controlled with β-blockers and
CCBs. The reports of two large trials comparing nitrates with
placebo showed no diﬀerence in mortality with the use of
nitrates [46, 47]. Hence, nitrates are not recommended to
reduce cardiac events but only to relieve angina, control BP,
and manage pulmonary congestion. Nitrates combined with
hydralazine have survival benefit in selectedHF patients [41].
However, individuals taking nitrates should be advised not
to use phosphodiesterase inhibitors such as sildenafil, as the
combination of both may cause severe hypotension.
3.6. Angiotensin-Converting Enzyme. ACE inhibitors are rec-
ommended for use in all patients after MI. Two major trials,
the European Trial on Reduction of Cardiac Events with
Perindopril in Stable Coronary Artery Disease (EUROPA)
and Heart Outcome Prevention Evaluation (HOPE) study,
showed the cardioprotective eﬀect of ACE inhibitor in
hypertensive CHD patients [48–51]. In the EUROPA study,
12,218 patients were randomized to treatment with an
ACE inhibitor (perindopril) or placebo. Individuals in the
perindopril group had significantly less MI, CVS death, or
cardiac arrest [48]. The HOPE study involved 9,297 patients
with CVS risk factors, who were randomized to ramipril
or placebo. Approximately half of the study population had
hypertension. Ramipril therapy was associated with small
(3/2mmHg) reduction in BP but significant reduction in
CVS death, stroke, and MI [49, 50]. These cardioprotective
eﬀects were initially thought to be independent of BP
control, until a subgroup analysis of the HOPE trial revealed
a significant reduction in 24-hour ambulatory BP with
ramipril that was not found in the main trial that measured
only oﬃce BP [51]. In another trial, the Prevention of Events
with Angiotensin Converting Enzyme inhibition (PEACE),
involving stable CHD patients with normal or slightly
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reduced ejection fraction, there was no diﬀerence between
trandolapril therapy and placebo in the incidence of MI or
coronary revascularization, despite 4.4/3.6mmHg reduction
in BP [52]. The findings of this study raised question about
the usefulness of ACE inhibitors in low-risk CHD patients
with normal LV systolic function. Thus, ACE inhibitors are
indicated for all hypertensive patients with acute MI who
have no contraindications, especially if there is associated
depressed LV systolic function (LVEF < 40%) [53, 54].
3.7. Angiotensin-Receptor Blockers. In individuals who are
ACE inhibitor intolerant or allergic, angiotensin receptors
blockers (ARBs) have been shown to be an eﬀective alter-
native in the treatment of hypertension, CHD, and HF.
Emerging data appear to support the use of ARBs in MI. In
the VALIANT study, the ARB, valsartan was as eﬀective as
captopril in patients at high risk of CVS events after MI [55,
56]. Among 15,245 hypertensive patients that were enrolled
in the Valsartan Antihypertensive Long-term Use Evaluation
(VALUE) trial, the ARB, valsartan, and CCB, amlodipine had
similar primary protection against CVS events [40]. Hence,
ARB appears to be a good substitute in those individuals in
which ACEI is contraindicated.
3.8. Diuretic. The ALLHAT trial clearly showed the benefit
of thiazide diuretic in the treatment of hypertension [37–
39], although there are concerns about the contribution
of the metabolic eﬀects of thiazide to CHD risk [57]. The
eﬀectiveness of thiazide in controlling BP and preventing
CVS events has been demonstrated in several studies [58–
60], but their use in the setting of acute MI is not encouraged
and if at all required, should be done with caution. While
there is an ongoing debate over whether the clinical benefits
observed with thiazide-type diuretic are drug specific, it is
not unreasonable to assume that there is a “class eﬀect,” given
the high degree of homogeneity in the mechanism of action
of this group of antihypertensive agents.
3.9. Combination and Adjunctive Therapy. The control of
BP is more important than the choice of antihypertensive
agent in the prevention CHD and other complications of
hypertension [61, 62]. Research has shown that eﬀective
combination of antihypertensive agents is usually required
to achieve and sustain long-term BP control [1]. Therefore,
the most important strategy for achieving target BP level is
by using combination therapy most especially in individuals
with stage 2 hypertension. Other adjunctive therapies such as
antiplatelet therapy and the use of statins are also encouraged
for lowering atherosclerotic burden in CHD patients. Non-
pharmacological therapy such as regular exercise, smoking
cessation, healthy diet, and healthful psychosocial func-
tioning should be emphasized in all patients, even when
antihypertensive agents are being used.
4. Conclusion
The target BP in hypertensive patients with CHD is
<130/80mmHg with caution in lowering the DBP below
60mmHg. To achieve this target, eﬀective combination anti-
hypertensive drug therapy is usually required to achieve and
sustain long-term BP control. Treatment regimen should
include β-blocker, ACE inhibitor, or ARB, most especially if
there is LV systolic dysfunction and/or diabetes mellitus, and
possibly a thiazide diuretic. CCBs can be used as alternative
to β-blocker or added to the basic regimen, and nitrates
are useful for relieve of ischemic pain. The overall goal
of therapy is to reduce morbidity and mortality associated
with both hypertension and CHD. As more data from
hypertension trials are made available, we anticipate changes
in the recommendations of the forthcoming JNC 8.
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